Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18662902 | ENDOCRINE CELLS THAT EXPRESS CHROMOGRANIN A | May 2024 | August 2025 | Abandon | 15 | 2 | 1 | No | No |
| 18050237 | METHOD FOR PRESSURIZING CELLS GROWN IN HYDROGEL TO INDUCE HYPERTROPHY | October 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17947884 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | September 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17909584 | BIOCOMPATIBLE SCAFFOLDS FOR CULTURING POST NATAL PROGENITOR CELLS | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17903271 | METHODS OF IN-OVO SCREENING OF ANTI-CANCER THERAPIES | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17822601 | COMPOSITION FOR SIMULTANEOUSLY MODIFYING AMINO ACIDS OF SITE 736 AND SITE 738 OF PAPN GENE AND APPLICATION THEREOF | August 2022 | February 2025 | Abandon | 30 | 3 | 0 | No | No |
| 17801669 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | August 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17760064 | METHOD FOR ISOLATING AUTOLOGOUS TUMOR ANTIGEN-REACTIVE CD8 T CELL BY USING CD71, AND APPLICATION THEREOF | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17841941 | USE OF A PLATELET DRY POWDER FOR RELIEVING INFLAMMATION OR INJURY IN A PORTION OF RESPIRATORY TRACT (OR THE AIRWAY) | June 2022 | March 2024 | Allow | 21 | 2 | 0 | No | No |
| 17776071 | SPIN-AGGREGATED NEURAL MICROSPHERES AND THE APPLICATION THEREOF | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17726116 | VIRAL MEDIATED GENE DELIVERY FOR TRANSIENT EXPRESSION OF PROTEINS | April 2022 | February 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17763552 | METHODS FOR TREATING ACUTE WOUNDS AND IMPROVING OUTCOMES | March 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17642199 | CULTURE METHOD FOR RETINAL ORGANOIDS | March 2022 | August 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17686878 | MODELS AND METHODS TO ESTABLISH PERFUSED VASCULARIZED TISSUES IN THREE-DIMENSIONAL IN VITRO CULTURE | March 2022 | January 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17638133 | Combinatorial Adenine and Cytosine DNA Base Editors | February 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17631917 | METHOD AND SYSTEM FOR CULTIVATING CELLS IN MEDIA-EXCHANGING WELLS | February 2022 | August 2025 | Allow | 43 | 1 | 1 | No | No |
| 17631645 | MEDIUM COMPOSITION FOR ENHANCING WNT PROTEIN ACTIVITY | January 2022 | July 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17630810 | THERAPEUTIC DRUGS FOR FIBROSIS, INFLAMMATION, AND/OR AGING DISEASES | January 2022 | July 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17629688 | BOVINE MONOCYTE-DERIVED MACROPHAGE IN CULTURE SYSTEM AND METHODS FOR MEASURING INNATE IMMUNITY | January 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17629395 | RECOMBINANT VECTOR FOR HIGH-EXPRESSION OF PROTEINS IN YEASTS | January 2022 | August 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17622022 | METHOD FOR PRODUCING NUCLEIC ACID-ENCAPSULATED AAV HOLLOW PARTICLE | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17543308 | MICROBIAL COLLECTION FORMULATIONS, DEVICES AND SYSTEMS | December 2021 | October 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17614916 | FUNCTIONAL ASTROCYTES DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAME | November 2021 | November 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17595429 | CELL CULTURE SUBSTRATE FOR CULTIVATING ADHERENT CELLS | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17610410 | GABA AGONISTS AND ANTAGONISTS AFFECT DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS AND MEGAKARYOCYTE PROGENITORS | November 2021 | February 2026 | Allow | 52 | 3 | 0 | Yes | No |
| 17518891 | NOVEL EUKARYOTIC CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A PRODUCT OF INTEREST | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17608741 | AUXOTROPHIC SELECTION METHODS | November 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17607097 | AFFINITY-BASED MULTIPLEXING FOR LIVE-CELL MONITORING OF COMPLEX CELL POPULATIONS | October 2021 | January 2026 | Abandon | 51 | 2 | 1 | Yes | No |
| 17606280 | AAV VECTORS ENCODING MINI-PCDH15 AND USES THEREOF | October 2021 | December 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17602060 | A Method of Altering a Differentiation Status of a Cell | October 2021 | January 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17594072 | HUMAN CARDIOMYOCYTE SEPARATION REAGENT, CULTURE MEDIUM, SEPARATION METHOD, AND CULTURE METHOD | October 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17442386 | AAV MUTANT HAVING BRAIN-TARGETING PROPERTY | September 2021 | July 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17441693 | Adult Liver Progenitor Cells for Treating Acute-On-Chronic Liver Failure | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17438603 | CELL COMPOSITION, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE COMPRISING SAME | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17472310 | Carrier Peptide Fragment and Use Thereof | September 2021 | January 2026 | Allow | 52 | 2 | 0 | Yes | Yes |
| 17436265 | MASS CULTURE OF PLURIPOTENT STEM CELLS | September 2021 | October 2025 | Abandon | 49 | 2 | 0 | Yes | No |
| 17436205 | PREPARATION AND EXTENDED CULTURE OF VASCULAR ENDOTHELIAL PROGENITOR CELL | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | Yes | No |
| 17428592 | OSTEOBLAST CELL-MIXTURE, AND IMPLEMENTATIONS THEREOF | August 2021 | April 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17310387 | COMPOSITION AND APPLICATION THEREOF | July 2021 | January 2026 | Abandon | 54 | 3 | 1 | No | No |
| 17424825 | COMPOSITIONS AND METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS (HSCS) | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17377312 | Synthesis of High Molecular Weight Proteins Using Inteins | July 2021 | December 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17351115 | COMPOSITIONS AND METHODS FOR IMPLANTATION OF PROCESSED ADIPOSE TISSUE AND PROCESSED ADIPOSE TISSUE PRODUCTS | June 2021 | February 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17413641 | PHARMACEUTICAL COMPOSITION FOR TREATING PANCREATITIS, COMPRISING CLONAL STEM CELLS | June 2021 | November 2025 | Abandon | 53 | 3 | 0 | No | No |
| 17311472 | Microfluidic Device Facilitating Perfusion of Mammalian and Human Tissue Constructs | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17298784 | USE OF ANIMAL ORIGINATED CORNEA MEMBRANE PRODUCTS IN TREATMENT OF EYE AND OUT OF EYE WOUNDS | June 2021 | March 2026 | Abandon | 58 | 4 | 0 | Yes | No |
| 17309449 | EXPANSION OF NATURAL KILLER CELLS AND ILC3 CELLS WITH NOVEL AROMATIC COMPOUNDS | May 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17291661 | Osteoblasts derived from oral neuroectodermal stem cells and their use in jaw repair | May 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17290470 | ADIPOCYTE MEDIATED DELIVERY OF ANTICANCER THERAPEUTICS | April 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17288636 | METHOD FOR PRODUCING INSULIN-PRODUCING CELLS, AND COMPOSITION | April 2021 | January 2026 | Abandon | 56 | 3 | 1 | Yes | No |
| 17284673 | ADENO-ASSOCIATED VIRUS HAVING A VARIANT CAPSID PROTEIN, AND USE THEREOF | April 2021 | September 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17283955 | CULTURE MEDIUM FOR GROWTH OF NEURAL STEM CELLS | April 2021 | December 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 17283263 | BIOLOGIC TISSUE PROCESSING DEVICE | April 2021 | January 2026 | Abandon | 57 | 3 | 1 | No | No |
| 17283503 | CARRIER FOR CELL CULTURE COMPRISING MICROCAPSULES CONTAINING NATURAL OIL | April 2021 | July 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17281979 | A GLIA CELL AND NEURON CO-CULTURE SYSTEM AND METHOD | March 2021 | July 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17279294 | METHODS AND USES FOR DETERMINING OSTEOGENIC POTENTIAL OF IN VITRO DIFFERENTIATED CELLS | March 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17278938 | METHODS FOR DIFFERENTIATING MESENCHYMAL STEM CELLS | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17054097 | Combined Purification and Concentration by Deterministic Lateral Displacement With Recirculation of Product | March 2021 | August 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17275096 | Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy | March 2021 | March 2026 | Allow | 60 | 5 | 1 | Yes | No |
| 17269278 | COMPOSITION AND METHOD FOR PRESERVING OR CULTURING OCULAR CELLS | February 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17267545 | CRYOPRESERVATION MEDIUM FOR UMBILICAL CORD MSCS DERIVED FROM WHARTON'S JELLY | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17168256 | NON-HUMAN ANIMALS HAVING A HUMANIZED A PROLIFERATION-INDUCING LIGAND GENE | February 2021 | June 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17262302 | Method for Producing Dental Pulp-Derived Cells | January 2021 | October 2025 | Abandon | 57 | 4 | 1 | No | No |
| 17115968 | Compositions and Methods for Treating, Ameliorating, and/or Preventing Viral Infections | December 2020 | June 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16972379 | niPSCs DERIVED FROM SOMATIC CELLS | December 2020 | February 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17088977 | HUMAN ANTI-AAV2 CAPSID POLYCLONAL ANTIBODY EPITOPES | November 2020 | August 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16981696 | METHOD AND SYSTEM FOR 3D CELL CULTURE AND USE THEREOF | September 2020 | May 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16648540 | METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PRODUCT, AND METHOD FOR PRODUCING BLOOD PRODUCT | March 2020 | May 2024 | Allow | 50 | 3 | 0 | No | No |
| 16646956 | Ex Vivo Maintenance and Expansion of Stem Cells | March 2020 | February 2026 | Abandon | 60 | 5 | 1 | Yes | No |
| 16624344 | ISOLATION DEVICE FOR ADIPOSE-DERIVED STROMAL VASCULAR FRACTION | December 2019 | January 2026 | Abandon | 60 | 4 | 1 | No | No |
| 16664182 | READY-TO-USE CRYOPRESERVED CELLS | October 2019 | October 2023 | Abandon | 47 | 4 | 0 | No | Yes |
| 16266975 | Engineered Stem Cell Therapy for Cardiac Repair | February 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BEHARRY, ZANNA MARIA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BEHARRY, ZANNA MARIA works in Art Unit 1632 and has examined 51 patent applications in our dataset. With an allowance rate of 15.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner BEHARRY, ZANNA MARIA's allowance rate of 15.7% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BEHARRY, ZANNA MARIA receive 1.96 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BEHARRY, ZANNA MARIA is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.3% benefit to allowance rate for applications examined by BEHARRY, ZANNA MARIA. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.2% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.4% of cases where such amendments are filed. This entry rate is in the 27% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.